A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia

Trial Profile

A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2012

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 04 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Results reported in a Cephalon media release.
    • 03 Jun 2010 Based on the results of this trial, Cephalon has decided not to move forward with the clinical program, according to a Cephalon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top